Flu News and Research RSS Feed - Flu News and Research

Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Hoaglund Enterprises awarded contract to evaluate Avian Flu affected equipment

Hoaglund Enterprises, Inc.,dba Asset Equipment Appraisals & Brokerage, a leading Nationally Certified Appraisal company is pleased to announce that they have been awarded a contract to appraise Avian Flu affected equipment that cannot be disinfected on infected farms by the USDA. [More]
Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Doctors at Cincinnati Children's Hospital Medical Center want to remind parents about the importance of immunizing their children when preparing to send their children back to school. [More]
FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. [More]
New mathematical simulation model helps manage ICU bed occupancy effectively

New mathematical simulation model helps manage ICU bed occupancy effectively

The critical care doctor Julio Barado-Hualde (Villava, Navarre, 1965) has developed a mathematical simulation model that enables the occupancy of beds in an ICU (Intensive Care Unit) to be predicted so that they can be managed more effectively. This research, which focusses on the Hospital Complex of Navarre, is part of his PhD thesis read at the NUP/UPNA-Public University of Navarre. [More]
SutroVax completes $22 million Series A financing

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively. [More]
AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

AS03 and MF59 adjuvants increase immune responses to two doses of H7N9 influenza vaccine

In a phase 2 trial that included nearly 1,000 adults, the AS03 and MF59 adjuvants (a component that improves immune response of inactivated influenza vaccines) increased the immune responses to two doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest amount of antibody response, according to a study in the July 21 issue of JAMA. [More]
Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

Elderberry supplement can provide protection from cold, flu-like symptoms following long-haul flights

The negative health effects of international air travel are well documented but now it seems that the common elderberry can provide some relief. [More]
Researchers devise way to induce protective immunity in mice against influenza viruses

Researchers devise way to induce protective immunity in mice against influenza viruses

A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. [More]
TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

TGen, NAU to jointly develop quick, affordable and accurate test to diagnose Lyme disease

Focus On Lyme, an initiative sponsored by the Leadership Children's Foundation of Gilbert, Ariz., has donated $75,000 to the Translational Genomics Research Institute to support research into the development of a quick, affordable and accurate method of diagnosing Lyme disease. [More]
GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK starts shipping FLUARIX QUADRIVALENT (Influenza Vaccine) to US healthcare providers

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to US healthcare providers, following licensing and lot-release approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research. [More]
New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

New dissolvable microneedle patch could make flu vaccination easier, safer and less painful

Flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine, according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch - the only vaccination system of its kind - could make vaccination easier, safer and less painful. [More]
Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others. [More]
Vanderbilt investigators develop potential antibody treatments against chikungunya

Vanderbilt investigators develop potential antibody treatments against chikungunya

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Vanderbilt University Medical Center's James Crowe, M.D., Ann Scott Carell Professor and director of the Vanderbilt Vaccine Center, and his team are reporting the first large panel of antibody treatments against this disease in the current issue of Cell Host and Microbe. [More]
Study could provide paradigm shift in treatment of age-related disease, cancer

Study could provide paradigm shift in treatment of age-related disease, cancer

Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies. [More]
Creating more effective vaccines against flu virus

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. [More]
Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Is it possible to predict the evolution of the influenza virus? Or how rapidly bacteria evolve resistance to antibiotics? Or even how cancer cells spread inside a human being? These are some of the main topics of discussion that bring together renowned scientists from all over the world at the scientific conference "Forecasting evolution?" held at the Calouste Gulbenkian Foundation (FCG; Portugal) from 8th to 11th July. [More]
BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

​BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program. [More]
Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events, which are expected to increase in frequency and intensity due to climate change, are associated with increased risk of Salmonella infections, according to a study led by researchers from the University of Maryland School of Public Health. [More]
Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans. [More]
National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

The University of Pittsburgh School of Medicine will be leading a $1.5 million national trial to examine methods to reduce unnecessary use of antibiotics in post-acute and long-term care (PA/LTC) facilities. [More]
Advertisement
Advertisement